Table 1.
Characteristics of the training and validation cohorts.
| Development set number (%) | Validation set number (%) | P adj | |
|---|---|---|---|
| 600 (60.9%) | 385 (39.0%) | ||
| Mean age, years (SD) | 57.5 (10.5) | 58.2 (10.5) | 0.719 |
| Gender | 0.876 | ||
| Male | 383 (63.8%) | 241 (62.5%) | |
| Female | 140 (23.3%) | 85 (22.0%) | |
| N/A | 77 (12.8%) | 59 (15.3%) | |
| Tumor category | 0.876 | ||
| T1 | 118 (19.7%) | 59 (15.3%) | |
| T2 | 204 (34%) | 120 (31.2%) | |
| T3 | 120 (20%) | 66 (17.1%) | |
| T4 | 129 (21.5%) | 70 (18.2%) | |
| N/A | 29 (4.8%) | 70 (18.2%) | |
| Nodal category | 0.008 | ||
| N0 | 135 (22.5%) | 92 (23.9%) | |
| N1 | 99 (16.5%) | 39 (10.1%) | |
| N2 | 40 (6.7%) | 8 (2.1%) | |
| N2A | 54 (9%) | 45 (11.7%) | |
| N2B | 171 (28.5%) | 90 (23.4%) | |
| N2C | 49 (8.2%) | 18 (4.7%) | |
| N3 | 28 (4.7%) | 17 (4.4%) | |
| N/A | 24 (4.0%) | 76 (19.7%) | |
| Smoking history | 0.341 | ||
| Current | 200 (33.3%) | 137 (35.5%) | |
| Past | 163 (27.1%) | 92 (23.8%) | |
| Never | 142 (23.6%) | 69 (17.9%) | |
| N/A | 95 (15.8%) | 87 (22.5%) | |
| Treatment | |||
| Radiotherapy | 548 | 280 | 8.74×10−4 |
| Chemotherapy | 358 | 133 | 9.21×10−12 |
| Surgery | 264 | 175 | 0.022 |
| Recurrence | 0.493 | ||
| Censored | 352 (58.7%) | 237 (61.5%) | |
| Events | 142 (23.7%) | 79 (20.5%) | |
| N/A | 106 (17.6%) | 69 (18%) | |
| Overall survival | 0.002 | ||
| Censored | 373 (62.2%) | 168 (43.6%) | |
| Events | 193 (32.2%) | 144 (37.4%) | |
| N/A | 34 (5.6%) | 73 (19%) | |
| Disease-specific survival | 1.01×10−4 | ||
| Censored | 443 (73.8%) | 201 (52.2%) | |
| Events | 108 (18%) | 101 (26.2%) | |
| N/A | 49 (8.2%) | 83 (21.6%) | |
| Biomarkers, H-score (SD) | |||
| BCL2 | 64.5 (95.2) | 60.0 (88.5) | 0.639 |
| COX2 | 146.6 (66.7) | 148.1 (63.1) | 0.876 |
| CyclinD1 | 124.8 (107.0) | 129.2 (102.2) | 0.639 |
| EGFR external | 129.4 (79.3) | 150.1 (81.9) | 0.001 |
| HIF1alpha | 28.1 (46.6) | 27.7 (44.4) | 0.549 |
| p16 | 163.9 (126.1) | 151.1 (130.8) | 0.596 |
| PLK1 | 34.2 (30.8) | 37.6 (29.5) | 0.041 |
| Survivin | 62.9 (37.6) | 71.9 (36.9) | 0.002 |
| HR-HPV ISH | 0.83 | ||
| 0 | 368 (61.3%) | 245 (63.6%) | |
| 1 | 160 (26.7%) | 113 (29.4%) | |
| N/A | 72 (12.0%) | 27 (7.0%) | |
| TILs | 0.639 | ||
| 1 | 89 (14.8%) | 67 (17.4%) | |
| 2 | 192 (32.0%) | 177 (45.9%) | |
| 3 | 119 (19.8%) | 94 (24.4%) | |
| N/A | 200 (33.3%) | 47 (12.2%) |
Note: Numbers in parentheses are percentages where specified, otherwise standard deviation. All staging was performed according to AJCC/UICC TNM 7th edition manual.